Jazz Pharmaceuticals (NASDAQ:JAZZ) Sees Large Volume Increase on Analyst Upgrade

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) saw strong trading volume on Thursday after Truist Financial raised their price target on the stock from $264.00 to $281.00. Truist Financial currently has a buy rating on the stock. Approximately 1,087,428 shares traded hands during trading, an increase of 15% from the previous session’s volume of 941,950 shares.The stock last traded at $247.8670 and had previously closed at $249.29.

A number of other equities analysts also recently commented on JAZZ. Wells Fargo & Company raised their price objective on Jazz Pharmaceuticals from $285.00 to $300.00 and gave the stock an “overweight” rating in a report on Tuesday, August 4th. Royal Bank Of Canada increased their target price on shares of Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. UBS Group reaffirmed a “buy” rating and set a $315.00 price target on shares of Jazz Pharmaceuticals in a research report on Tuesday, August 4th. Canaccord Genuity Group set a $300.00 price objective on shares of Jazz Pharmaceuticals in a research note on Wednesday. Finally, Sanford C. Bernstein reissued a “market perform” rating on shares of Jazz Pharmaceuticals in a research report on Tuesday, June 9th. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $279.00.

Insider Buying and Selling at Jazz Pharmaceuticals

In related news, EVP Neena M. Patil sold 1,200 shares of the business’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total value of $278,196.00. Following the completion of the sale, the executive vice president directly owned 51,549 shares of the company’s stock, valued at $11,950,604.67. The trade was a 2.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bruce C. Cozadd sold 6,000 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were sold at an average price of $252.98, for a total value of $1,517,880.00. Following the sale, the director directly owned 360,682 shares in the company, valued at approximately $91,245,332.36. This represents a 1.64% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 14,357 shares of company stock worth $3,505,642 in the last 90 days. 4.10% of the stock is owned by corporate insiders.

Key Jazz Pharmaceuticals News

Here are the key news stories impacting Jazz Pharmaceuticals this week:

• Positive Sentiment: The FDA approved two Ziihera-based regimens for first-line treatment of advanced HER2-positive gastroesophageal adenocarcinoma. The broader label covers eligible patients with different HER2 levels and, in one regimen, regardless of PD-L1 status, expanding Ziihera’s addressable market and supporting expectations for significant commercial growth. FDA approves Ziihera regimens
• Positive Sentiment: Analysts raised their targets while maintaining Buy ratings: Needham increased its target from $292 to $310, and Truist lifted its target from $264 to $281. The revisions reflect optimism surrounding Ziihera’s new indication and Jazz’s growth prospects. Analyst price target increases
• Neutral Sentiment: Jazz priced $1.1 billion of 1.875% exchangeable senior notes due 2032, up from the previously announced $1.0 billion offering. Proceeds are being paired with concurrent ordinary-share repurchases, which could support per-share results but also increase leverage and create potential future dilution. Jazz prices exchangeable notes
• Negative Sentiment: Zacks Research reduced several forward EPS estimates, including FY2026 from $21.72 to $20.77 and FY2027 from $22.26 to $20.02. Estimates for Q3 and Q4 2026 and multiple 2027 quarters were also lowered, suggesting some pressure on near- to medium-term earnings expectations. A small increase in the Q2 2028 forecast to $6.09 provides only a partial offset.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the stock. Royal Bank of Canada raised its holdings in Jazz Pharmaceuticals by 96.5% during the first quarter. Royal Bank of Canada now owns 67,614 shares of the specialty pharmaceutical company’s stock worth $8,394,000 after purchasing an additional 33,210 shares in the last quarter. Goldman Sachs Group Inc. increased its position in shares of Jazz Pharmaceuticals by 147.7% during the 1st quarter. Goldman Sachs Group Inc. now owns 351,609 shares of the specialty pharmaceutical company’s stock valued at $43,652,000 after purchasing an additional 209,667 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its holdings in shares of Jazz Pharmaceuticals by 4.2% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 197,174 shares of the specialty pharmaceutical company’s stock valued at $24,479,000 after buying an additional 7,954 shares during the period. Focus Partners Wealth boosted its stake in Jazz Pharmaceuticals by 3.4% during the first quarter. Focus Partners Wealth now owns 4,623 shares of the specialty pharmaceutical company’s stock valued at $574,000 after buying an additional 154 shares in the last quarter. Finally, Geneos Wealth Management Inc. grew its holdings in Jazz Pharmaceuticals by 57.6% during the first quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock worth $47,000 after acquiring an additional 137 shares during the period. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Trading Down 0.6%

The company has a debt-to-equity ratio of 0.69, a current ratio of 1.78 and a quick ratio of 1.58. The business has a fifty day moving average of $246.38 and a 200-day moving average of $217.52. The stock has a market capitalization of $16.08 billion, a price-to-earnings ratio of 17.10, a price-to-earnings-growth ratio of 0.23 and a beta of 0.32.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Monday, August 3rd. The specialty pharmaceutical company reported $5.71 earnings per share (EPS) for the quarter, missing the consensus estimate of $6.18 by ($0.47). The firm had revenue of $1.21 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Jazz Pharmaceuticals had a return on equity of 33.97% and a net margin of 20.45%.Jazz Pharmaceuticals’s revenue was up 15.5% on a year-over-year basis. During the same quarter in the prior year, the business posted ($8.25) earnings per share. On average, equities analysts anticipate that Jazz Pharmaceuticals PLC will post 21.66 earnings per share for the current fiscal year.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.